("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study ...
Having your electricity disconnected is more common in Oklahoma than any other state.
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly ...
Coweta’s Planning Commission voted 4-1 deny a rezoning request to build a proposed data center on 270 acres of land between Highways 72 and 51-B, north of the Arkansas River. Before public comment ...
Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line ...
Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor has outperformed Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO). In the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results